Valuation: Unicycive Therapeutics, Inc.

Market Cap 15Cr 13Cr 12Cr 11Cr 21Cr 1.42TCr 21Cr 143.47Cr 56Cr 700.34Cr 56Cr 54Cr 2.42TCr P/E 2026 *
-3.82x
P/E 2027 * 1.05x
Enterprise Value 15Cr 13Cr 12Cr 11Cr 21Cr 1.42TCr 21Cr 143.47Cr 56Cr 700.34Cr 56Cr 54Cr 2.42TCr EV / Sales 2026 *
38.9x
EV / Sales 2027 * 0.51x
Free-Float
97.64%
Yield 2026 *
-
Yield 2027 * 42.6%
1 day-1.10%
1 week+0.37%
Current month+15.14%
1 month-24.26%
3 months-25.93%
6 months-21.51%
Current year-6.41%
1 week 5.3
Extreme 5.305
5.87
1 month 3.93
Extreme 3.93
8.05
Current year 3.93
Extreme 3.93
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
36.2
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 18/08/2016
Director of Finance/CFO 64 01/03/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 53 18/08/2016
Director/Board Member 58 01/01/2018
Director/Board Member 58 06/09/2023
Date Insider Type Main position Quantity % Market Cap.
14/05/26 Free

Director

1,26,300 0.5004%
14/05/26 Free

Director

1,26,300 0.5004%
14/05/26 Free

Chief Executive Officer

7,62,200 3.0201%
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%+0.37%+10.88%-55.74% 15Cr
-0.42%+6.29%+56.51%+70.75% 5.73TCr
-1.92%+6.03%+40.64%+80.66% 5.5TCr
-0.46%-1.29%+2.86%+425.15% 2.32TCr
-2.97%-2.35%-22.53%-15.34% 2.26TCr
-1.13%+1.05%+20.81%-7.73% 2.05TCr
+0.29%+2.00%+25.81%-29.96% 1.76TCr
-0.10%+1.88%+34.42%+545.91% 1.57TCr
-1.30%-5.02%+170.77%+310.94% 1.45TCr
-0.50%-0.98%+21.43%+179.36% 1.39TCr
Average -0.96%+1.19%+36.16%+150.40% 2.4TCr
Weighted average by Cap. -1.05%+2.09%+38.36%+136.72%

Financials

2026 *2027 *
Net sales 38.04L 33.41L 31.07L 28.51L 53.58L 37Cr 54.4L 3.69Cr 1.44Cr 18Cr 1.43Cr 1.4Cr 62Cr 29Cr 25Cr 24Cr 22Cr 41Cr 2.78TCr 41Cr 279.71Cr 109.28Cr 1.37TCr 108.26Cr 105.92Cr 4.72TCr
Net income -4.03Cr -3.54Cr -3.29Cr -3.02Cr -5.68Cr -388.45Cr -5.77Cr -39Cr -15Cr -190.98Cr -15Cr -15Cr -660.3Cr 19Cr 16Cr 15Cr 14Cr 26Cr 1.79TCr 27Cr 180.6Cr 71Cr 881.55Cr 70Cr 68Cr 3.05TCr
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
24/26/24 $5.400 -1.10% 4,97,709
23/26/23 $5.460 -1.97% 6,49,585
22/26/22 $5.570 -2.11% 5,95,078
21/26/21 $5.690 +4.40% 11,39,169
20/26/20 $5.450 +1.30% 6,47,201
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.400USD
Average target price
38.59USD
Spread / Average Target
+614.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock